Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection-Reference-Cited by-同舟云学术

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Published:2022-05-23 Issue:1 Volume:11 Page:1343-1345
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Suah Jing Lian¹^ORCID,Tng Boon Hwa¹,Tok Peter Seah Keng¹^ORCID,Husin Masliyana¹^ORCID,Thevananthan Thevesh²,Peariasamy Kalaiarasu M.¹^ORCID,Sivasampu Sheamini¹^ORCID

Affiliation:

1. Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia

2. Disease Control Division, Ministry of Health Malaysia, Putrajaya, Malaysia

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2022.2072773

Reference10 articles.

1. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

2. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

3. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

4. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

5. COVIDNOW in Malaysia: the official Malaysia government website for data and insights on COVID-19. Malaysia: Ministry of Health Malaysia; p. c2021–2022 [cited 2022 Feb 28]. Available from: https://covidnow.moh.gov.my/.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence;Infectious Disorders - Drug Targets;2024-11

2. Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac;Vaccine;2024-11

3. Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization;PLOS ONE;2024-09-13

4. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina;Frontiers in Immunology;2024-05-14

5. Effectiveness of COVID-19 vaccines among children 6–11 years against hospitalization during Omicron predominance in Malaysia;Scientific Reports;2024-03-08